The new methods will produce high-purity populations of neural stem cells (NSC) from hpSC and their therapeutically valuable derivatives at a low cost.
The method is capable of generating sufficient quantities of neuronal cells for ISCO’s pre-clinical and clinical studies.
The company has also developed a new high-throughput cell culture method for producing cGMP grade hpSC necessary for commercial and therapeutic applications.
ISCO is focused on the therapeutic applications of hpSCs and the development and commercialization of cell-based research and cosmetic products.